BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer

Trial Profile

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BACCI
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Nov 2025 to 30 Jun 2021.
    • 16 Oct 2017 Planned primary completion date changed from 1 Nov 2020 to 30 Nov 2020.
    • 16 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top